Crescita Therapeutics Inc. (CTX.TO)
CAD 0.59
(0.0%)
CAD 0.59
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.13 Million CAD | -22.73% |
| 2022 | -6.62 Million CAD | 21.72% |
| 2021 | -8.46 Million CAD | 35.15% |
| 2020 | -13.05 Million CAD | -69.05% |
| 2019 | -7.72 Million CAD | -84.69% |
| 2018 | -4.18 Million CAD | -55.8% |
| 2017 | -2.68 Million CAD | -63.3% |
| 2016 | -1.64 Million CAD | -243.72% |
| 2015 | -478 Thousand CAD | -7.9% |
| 2014 | -443 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -7.97 Million CAD | 4.88% |
| 2024 Q1 | -8.38 Million CAD | -3.12% |
| 2023 FY | -8.13 Million CAD | -22.73% |
| 2023 Q1 | -8.76 Million CAD | -32.24% |
| 2023 Q2 | -8.81 Million CAD | -0.59% |
| 2023 Q3 | -8.71 Million CAD | 1.16% |
| 2023 Q4 | -8.13 Million CAD | 6.66% |
| 2022 Q3 | -9.12 Million CAD | -3.73% |
| 2022 Q1 | -8.95 Million CAD | -5.79% |
| 2022 FY | -6.62 Million CAD | 21.72% |
| 2022 Q2 | -8.79 Million CAD | 1.8% |
| 2022 Q4 | -6.62 Million CAD | 27.36% |
| 2021 Q1 | -10.85 Million CAD | 16.82% |
| 2021 Q4 | -8.46 Million CAD | 8.9% |
| 2021 Q3 | -9.29 Million CAD | 7.71% |
| 2021 Q2 | -10.06 Million CAD | 7.28% |
| 2021 FY | -8.46 Million CAD | 35.15% |
| 2020 Q2 | -7.87 Million CAD | -0.13% |
| 2020 Q1 | -7.86 Million CAD | -1.84% |
| 2020 Q4 | -13.05 Million CAD | -4.04% |
| 2020 Q3 | -12.54 Million CAD | -59.35% |
| 2020 FY | -13.05 Million CAD | -69.05% |
| 2019 Q4 | -7.72 Million CAD | 1.42% |
| 2019 Q2 | -6.44 Million CAD | -15.68% |
| 2019 FY | -7.72 Million CAD | -84.69% |
| 2019 Q1 | -5.57 Million CAD | -33.37% |
| 2019 Q3 | -7.83 Million CAD | -21.43% |
| 2018 Q1 | -5.11 Million CAD | -90.76% |
| 2018 FY | -4.18 Million CAD | -55.8% |
| 2018 Q4 | -4.18 Million CAD | -9.17% |
| 2018 Q3 | -3.82 Million CAD | 19.12% |
| 2018 Q2 | -4.73 Million CAD | 7.5% |
| 2017 Q3 | -4.46 Million CAD | -219.97% |
| 2017 Q2 | 3.72 Million CAD | 31.08% |
| 2017 FY | -2.68 Million CAD | -63.3% |
| 2017 Q1 | 2.83 Million CAD | 272.73% |
| 2017 Q4 | -2.68 Million CAD | 39.88% |
| 2016 Q1 | -32.59 Million CAD | -6718.83% |
| 2016 Q4 | -1.64 Million CAD | 75.71% |
| 2016 Q3 | -6.76 Million CAD | 77.43% |
| 2016 Q2 | -29.97 Million CAD | 8.05% |
| 2016 FY | -1.64 Million CAD | -243.72% |
| 2015 FY | -478 Thousand CAD | -7.9% |
| 2015 Q1 | 445 Thousand CAD | 0.0% |
| 2015 Q4 | -478 Thousand CAD | 0.0% |
| 2014 FY | -443 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | -8.64 Million CAD | 5.978% |
| Avicanna Inc. | 1.32 Million CAD | 713.106% |
| Avant Brands Inc. | 17.93 Million CAD | 145.349% |
| Cardiol Therapeutics Inc. | -34.77 Million CAD | 76.617% |
| Knight Therapeutics Inc. | 10.33 Million CAD | 178.712% |
| MediPharm Labs Corp. | -15.68 Million CAD | 48.164% |
| OrganiGram Holdings Inc. | -33.7 Million CAD | 75.879% |
| Canopy Growth Corporation | 512.87 Million CAD | 101.585% |
| Willow Biosciences Inc. | -989 Thousand CAD | -722.144% |
| Auxly Cannabis Group Inc. | 142.88 Million CAD | 105.691% |